Novo Nordisk's 27% Profit Beat Gives the Wegovy Pill a Second Act
Published on 11/04/2026 at 14:31 | Editorial boerse-global.de
Novo Nordisk shares climbed 6.7% on Wednesday after the Danish drugmaker delivered a currency-adjusted operating profit that cleared analyst expectations and a Wegovy pill figure that came in well above consensus — a combination that gave the stock's advance a firmer footing than the raised full-year guidance alone.
The distinction matters for anyone trying to read the move. The beat came from the business itself, not merely from a lowered bar. Novo Nordisk reported adjusted operating profit of DKK 31,720 million for the third quarter of 2026, a 27% increase at constant exchange rates, which the company said exceeded expectations. Those growth rates are stated at constant currencies and describe that specific earnings line — they do not translate directly to other profit measures.
The pill clears its hurdle
Sales of the Wegovy tablet reached DKK 5,394 million, against a consensus of DKK 4.62 billion. The product-level surprise is what broadens the case: alongside the operating profit beat, a named product outperformed. That gives the rally more substance than a standalone change to the outlook. It says nothing, however, about where the product's margin goes from here.
The context is a full-year forecast that management had already lifted. Novo Nordisk expects adjusted sales and operating profit for 2026 to develop in a range of -2% to +2% at constant currencies. The band still permits either a decline or growth; the stronger quarterly figures do not narrow it.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A CFO change, filed separately
Alongside the numbers, Novo Nordisk announced a leadership transition. Finance chief Karsten Munk Knudsen will leave the company at the end of December 2026, with Luigi La Corte, currently CFO of Galderma, named as his successor. The change is a separate corporate item and was not among the drivers cited for Wednesday's share price move.
Heading into the release, the setup had been less encouraging. Results for the third quarter of 2026 were scheduled for publication before the market opened, and analysts had been expecting a year-on-year decline in revenue, according to media reports from the previous day. That made the print the immediate test — and raised the question of whether any improvement would rest on genuine product momentum rather than simply on expectations set low enough.
Jyske Bank had argued that Novo Nordisk would raise the lower bound of its 2026 guidance, pointing to the Wegovy pill launches and a stronger-than-expected trajectory for Ozempic. That was an analyst projection, not a company decision, and the two perspectives are not mutually exclusive: a projected revenue decline and a more favourable annual outlook can coexist. A lifted floor would signal a less downbeat view of the current year, but it would not by itself prove a durable competitive advantage — the operating rationale would have to carry that weight.
Lilly's trial data cast a longer shadow
Competition supplies an independent risk. Reuters reported on 28 October on Eli Lilly's comments about its investigational drug retatrutide, which in a diabetes study achieved better blood sugar control than Ozempic and more than double the weight loss. Retatrutide is still an investigational candidate; the comparison implies neither an accomplished shift in market share nor a quantifiable revenue impact for Novo Nordisk. Even so, it stands as a serious counterweight to the optimistic guidance thesis, and a near-term improvement in Ozempic would not automatically neutralise longer-run pressure.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Novo Nordisk is meanwhile continuing its share buyback programme, reporting further weekly repurchases on the previous day. The capital measure is a factor in its own right but no substitute for evidence of operating strength.
Next on the calendar are scientific venues where the product story can be examined beyond the quarterly numbers. Novo Nordisk has announced twelve contributions on clinical and care data for semaglutide at the Liver Meeting in Denver from 5 to 9 November. Further presentations are planned for ObesityWeek in Washington from 14 to 17 November, covering among other things CagriSema, care data for the Wegovy pill and STEP Young. Announced presentations are not positive results — but they offer the next opportunities to test the pipeline case alongside the financial guidance.
Ad
Novo Nordisk Stock: New Analysis - 4 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
